CA2629337A1 - Emploi d'ingenanes substitues par des groupements angeloyle en combinaison avec d'autres agents dans le traitement du cancer - Google Patents

Info

Publication number

CA2629337A1

CA2629337A1 CA002629337A CA2629337A CA2629337A1 CA 2629337 A1 CA2629337 A1 CA 2629337A1 CA 002629337 A CA002629337 A CA 002629337A CA 2629337 A CA2629337 A CA 2629337A CA 2629337 A1 CA2629337 A1 CA 2629337A1

Authority

CA

Canada

Prior art keywords

cancer

cell

agent

cells

euphorbia

Prior art date

2005-11-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 340
• 201000011510 cancer Diseases 0.000 title claims abstract description 219
• 239000003795 chemical substances by application Substances 0.000 claims abstract description 230
• 230000001093 anti-cancer Effects 0.000 claims abstract description 112
• 238000011282 treatment Methods 0.000 claims abstract description 80
• 238000000034 method Methods 0.000 claims abstract description 55
• 150000003839 salts Chemical class 0.000 claims abstract description 55
• JHORJRSRQZDYPZ-UHFFFAOYSA-N 1,1,4,7,9-pentamethyldodecahydro-1h-2,8a-methanocyclopenta[a]cyclopropa[e][10]annulene Chemical class CC1CC2C(C)(C)C2C2CC(C)CC3CC(C)CC31C2 JHORJRSRQZDYPZ-UHFFFAOYSA-N 0.000 claims abstract description 53
• 239000002246 antineoplastic agent Substances 0.000 claims abstract description 51
• 230000001225 therapeutic effect Effects 0.000 claims abstract description 43
• 210000004027 cell Anatomy 0.000 claims description 399
• 229960002993 ingenol mebutate Drugs 0.000 claims description 325
• VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 claims description 318
• VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical group C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 claims description 318
• 210000000440 neutrophil Anatomy 0.000 claims description 131
• 239000003814 drug Substances 0.000 claims description 73
• VEBVPUXQAPLADL-UHFFFAOYSA-N Ingenol Natural products C1=C(CO)C(O)C2(O)C(O)C(C)=CC32C(C)CC2C(C)(C)C2C1C3=O VEBVPUXQAPLADL-UHFFFAOYSA-N 0.000 claims description 68
• VEBVPUXQAPLADL-POYOOMFHSA-N ingenol Chemical compound C1=C(CO)[C@@H](O)[C@]2(O)[C@@H](O)C(C)=C[C@]32[C@H](C)C[C@H]2C(C)(C)[C@H]2[C@H]1C3=O VEBVPUXQAPLADL-POYOOMFHSA-N 0.000 claims description 68
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 66
• 229940079593 drug Drugs 0.000 claims description 60
• 230000000694 effects Effects 0.000 claims description 58
• 239000000203 mixture Substances 0.000 claims description 58
• 230000006907 apoptotic process Effects 0.000 claims description 54
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 53
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 47
• 231100000135 cytotoxicity Toxicity 0.000 claims description 41
• 230000003013 cytotoxicity Effects 0.000 claims description 40
• 238000009472 formulation Methods 0.000 claims description 40
• 230000004936 stimulating effect Effects 0.000 claims description 39
• 239000000427 antigen Substances 0.000 claims description 36
• 102000036639 antigens Human genes 0.000 claims description 36
• 108091007433 antigens Proteins 0.000 claims description 36
• 230000001404 mediated effect Effects 0.000 claims description 35
• 230000017074 necrotic cell death Effects 0.000 claims description 32
• 230000003213 activating effect Effects 0.000 claims description 30
• 230000025084 cell cycle arrest Effects 0.000 claims description 29
• 230000009758 senescence Effects 0.000 claims description 29
• 230000034994 death Effects 0.000 claims description 25
• 231100000517 death Toxicity 0.000 claims description 25
• 230000005764 inhibitory process Effects 0.000 claims description 25
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 22
• 210000003491 skin Anatomy 0.000 claims description 21
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 20
• 201000001441 melanoma Diseases 0.000 claims description 20
• 239000003085 diluting agent Substances 0.000 claims description 19
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 17
• 238000004519 manufacturing process Methods 0.000 claims description 16
• 206010039491 Sarcoma Diseases 0.000 claims description 15
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 14
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 13
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 13
• 240000001837 Euphorbia peplus Species 0.000 claims description 12
• 206010025323 Lymphomas Diseases 0.000 claims description 12
• 201000005962 mycosis fungoides Diseases 0.000 claims description 12
• 239000000126 substance Substances 0.000 claims description 12
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 10
• 208000017604 Hodgkin disease Diseases 0.000 claims description 10
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 10
• 208000032839 leukemia Diseases 0.000 claims description 10
• 201000008261 skin carcinoma Diseases 0.000 claims description 10
• 239000003937 drug carrier Substances 0.000 claims description 9
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
• 201000000582 Retinoblastoma Diseases 0.000 claims description 8
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 8
• 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 8
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
• 208000008383 Wilms tumor Diseases 0.000 claims description 8
• 208000025997 central nervous system neoplasm Diseases 0.000 claims description 8
• 206010017758 gastric cancer Diseases 0.000 claims description 8
• 208000014018 liver neoplasm Diseases 0.000 claims description 8
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
• 201000008106 ocular cancer Diseases 0.000 claims description 8
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 8
• 201000011549 stomach cancer Diseases 0.000 claims description 8
• 206010044412 transitional cell carcinoma Diseases 0.000 claims description 8
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
• 229960005486 vaccine Drugs 0.000 claims description 8
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
• 208000035475 disorder Diseases 0.000 claims description 7
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 7
• 206010006187 Breast cancer Diseases 0.000 claims description 6
• 208000026310 Breast neoplasm Diseases 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
• 206010060862 Prostate cancer Diseases 0.000 claims description 5
• 210000004556 brain Anatomy 0.000 claims description 5
• 208000020816 lung neoplasm Diseases 0.000 claims description 5
• 208000037819 metastatic cancer Diseases 0.000 claims description 5
• 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 5
• 208000030507 AIDS Diseases 0.000 claims description 4
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
• 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 4
• 201000004384 Alopecia Diseases 0.000 claims description 4
• 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims description 4
• 206010061424 Anal cancer Diseases 0.000 claims description 4
• 201000003076 Angiosarcoma Diseases 0.000 claims description 4
• 208000007860 Anus Neoplasms Diseases 0.000 claims description 4
• 208000032467 Aplastic anaemia Diseases 0.000 claims description 4
• 206010003571 Astrocytoma Diseases 0.000 claims description 4
• 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 4
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
• 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
• 206010004272 Benign hydatidiform mole Diseases 0.000 claims description 4
• 206010004593 Bile duct cancer Diseases 0.000 claims description 4
• 206010005003 Bladder cancer Diseases 0.000 claims description 4
• 206010005949 Bone cancer Diseases 0.000 claims description 4
• 208000018084 Bone neoplasm Diseases 0.000 claims description 4
• 206010006143 Brain stem glioma Diseases 0.000 claims description 4
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims description 4
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
• 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
• 208000006332 Choriocarcinoma Diseases 0.000 claims description 4
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
• 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 4
• 206010052465 Congenital poikiloderma Diseases 0.000 claims description 4
• 208000008334 Dermatofibrosarcoma Diseases 0.000 claims description 4
• 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims description 4
• 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 claims description 4
• 206010064581 Desmoplastic small round cell tumour Diseases 0.000 claims description 4
• 208000006402 Ductal Carcinoma Diseases 0.000 claims description 4
• 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 4
• 206010014733 Endometrial cancer Diseases 0.000 claims description 4
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
• 206010014967 Ependymoma Diseases 0.000 claims description 4
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
• 208000006168 Ewing Sarcoma Diseases 0.000 claims description 4
• 201000001342 Fallopian tube cancer Diseases 0.000 claims description 4
• 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 4
• 201000004939 Fanconi anemia Diseases 0.000 claims description 4
• 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
• 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 4
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
• 208000032612 Glial tumor Diseases 0.000 claims description 4
• 206010018338 Glioma Diseases 0.000 claims description 4
• 208000001258 Hemangiosarcoma Diseases 0.000 claims description 4
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
• 208000033640 Hereditary breast cancer Diseases 0.000 claims description 4
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
• 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 4
• 241000701806 Human papillomavirus Species 0.000 claims description 4
• 208000006937 Hydatidiform mole Diseases 0.000 claims description 4
• 208000037147 Hypercalcaemia Diseases 0.000 claims description 4
• 206010061252 Intraocular melanoma Diseases 0.000 claims description 4
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 4
• 206010023825 Laryngeal cancer Diseases 0.000 claims description 4
• 208000018142 Leiomyosarcoma Diseases 0.000 claims description 4
• 201000011062 Li-Fraumeni syndrome Diseases 0.000 claims description 4
• 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims description 4
• 206010062038 Lip neoplasm Diseases 0.000 claims description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
• 206010025282 Lymphoedema Diseases 0.000 claims description 4
• 208000004059 Male Breast Neoplasms Diseases 0.000 claims description 4
• 208000032271 Malignant tumor of penis Diseases 0.000 claims description 4
• 208000000172 Medulloblastoma Diseases 0.000 claims description 4
• 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 4
• 206010027406 Mesothelioma Diseases 0.000 claims description 4
• 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
• 208000014767 Myeloproliferative disease Diseases 0.000 claims description 4
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 4
• 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 4
• 206010029260 Neuroblastoma Diseases 0.000 claims description 4
• 208000009905 Neurofibromatoses Diseases 0.000 claims description 4
• 208000004485 Nijmegen breakage syndrome Diseases 0.000 claims description 4
• 208000010505 Nose Neoplasms Diseases 0.000 claims description 4
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 4
• 206010033128 Ovarian cancer Diseases 0.000 claims description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
• 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 4
• 208000002471 Penile Neoplasms Diseases 0.000 claims description 4
• 206010034299 Penile cancer Diseases 0.000 claims description 4
• 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 4
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
• 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 claims description 4
• 206010038389 Renal cancer Diseases 0.000 claims description 4
• 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
• 208000000791 Rothmund-Thomson syndrome Diseases 0.000 claims description 4
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 4
• 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
• 208000009359 Sezary Syndrome Diseases 0.000 claims description 4
• 208000021388 Sezary disease Diseases 0.000 claims description 4
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 4
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
• 206010057644 Testis cancer Diseases 0.000 claims description 4
• 208000000728 Thymus Neoplasms Diseases 0.000 claims description 4
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
• 206010046431 Urethral cancer Diseases 0.000 claims description 4
• 206010046458 Urethral neoplasms Diseases 0.000 claims description 4
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
• 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 4
• 102000012349 Uroplakins Human genes 0.000 claims description 4
• 108010061861 Uroplakins Proteins 0.000 claims description 4
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
• 201000005969 Uveal melanoma Diseases 0.000 claims description 4
• 208000014070 Vestibular schwannoma Diseases 0.000 claims description 4
• 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 4
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
• 208000004064 acoustic neuroma Diseases 0.000 claims description 4
• 208000017733 acquired polycythemia vera Diseases 0.000 claims description 4
• 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 4
• 231100000360 alopecia Toxicity 0.000 claims description 4
• 208000008524 alveolar soft part sarcoma Diseases 0.000 claims description 4
• 201000011165 anus cancer Diseases 0.000 claims description 4
• 208000002458 carcinoid tumor Diseases 0.000 claims description 4
• 201000010881 cervical cancer Diseases 0.000 claims description 4
• 201000002797 childhood leukemia Diseases 0.000 claims description 4
• 208000011654 childhood malignant neoplasm Diseases 0.000 claims description 4
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 4
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 4
• 201000004101 esophageal cancer Diseases 0.000 claims description 4
• 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims description 4
• 208000024519 eye neoplasm Diseases 0.000 claims description 4
• 201000010175 gallbladder cancer Diseases 0.000 claims description 4
• 208000003884 gestational trophoblastic disease Diseases 0.000 claims description 4
• 201000007116 gestational trophoblastic neoplasm Diseases 0.000 claims description 4
• 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
• 201000010536 head and neck cancer Diseases 0.000 claims description 4
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
• 208000025581 hereditary breast carcinoma Diseases 0.000 claims description 4
• 201000008298 histiocytosis Diseases 0.000 claims description 4
• 230000000148 hypercalcaemia Effects 0.000 claims description 4
• 208000030915 hypercalcemia disease Diseases 0.000 claims description 4
• 201000006866 hypopharynx cancer Diseases 0.000 claims description 4
• 201000002313 intestinal cancer Diseases 0.000 claims description 4
• 208000022013 kidney Wilms tumor Diseases 0.000 claims description 4
• 201000010982 kidney cancer Diseases 0.000 claims description 4
• 206010023841 laryngeal neoplasm Diseases 0.000 claims description 4
• 201000006721 lip cancer Diseases 0.000 claims description 4
• 206010024627 liposarcoma Diseases 0.000 claims description 4
• 201000007270 liver cancer Diseases 0.000 claims description 4
• 201000005202 lung cancer Diseases 0.000 claims description 4
• 208000002502 lymphedema Diseases 0.000 claims description 4
• 201000003175 male breast cancer Diseases 0.000 claims description 4
• 208000010907 male breast carcinoma Diseases 0.000 claims description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 4
• 208000016847 malignant urinary system neoplasm Diseases 0.000 claims description 4
• 206010051747 multiple endocrine neoplasia Diseases 0.000 claims description 4
• 206010028537 myelofibrosis Diseases 0.000 claims description 4
• 208000037830 nasal cancer Diseases 0.000 claims description 4
• 201000008026 nephroblastoma Diseases 0.000 claims description 4
• 208000007538 neurilemmoma Diseases 0.000 claims description 4
• 201000004931 neurofibromatosis Diseases 0.000 claims description 4
• 201000002575 ocular melanoma Diseases 0.000 claims description 4
• 201000005443 oral cavity cancer Diseases 0.000 claims description 4
• 201000006958 oropharynx cancer Diseases 0.000 claims description 4
• 201000008968 osteosarcoma Diseases 0.000 claims description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
• 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims description 4
• 201000001219 parotid gland cancer Diseases 0.000 claims description 4
• 201000002511 pituitary cancer Diseases 0.000 claims description 4
• 208000037244 polycythemia vera Diseases 0.000 claims description 4
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
• 208000003476 primary myelofibrosis Diseases 0.000 claims description 4
• 208000013860 rhabdoid tumor of the kidney Diseases 0.000 claims description 4
• 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
• 206010039667 schwannoma Diseases 0.000 claims description 4
• 201000000849 skin cancer Diseases 0.000 claims description 4
• 201000002314 small intestine cancer Diseases 0.000 claims description 4
• 206010062261 spinal cord neoplasm Diseases 0.000 claims description 4
• 206010042863 synovial sarcoma Diseases 0.000 claims description 4
• 201000003120 testicular cancer Diseases 0.000 claims description 4
• 201000009377 thymus cancer Diseases 0.000 claims description 4
• 201000002510 thyroid cancer Diseases 0.000 claims description 4
• 208000029387 trophoblastic neoplasm Diseases 0.000 claims description 4
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
• 201000004435 urinary system cancer Diseases 0.000 claims description 4
• 206010046766 uterine cancer Diseases 0.000 claims description 4
• 208000037965 uterine sarcoma Diseases 0.000 claims description 4
• 201000005102 vulva cancer Diseases 0.000 claims description 4
• 206010046885 vaginal cancer Diseases 0.000 claims description 3
• 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 claims 3
• 241000221079 Euphorbia <genus> Species 0.000 description 168
• 241000699670 Mus sp. Species 0.000 description 70
• 241001465754 Metazoa Species 0.000 description 59
• 150000001875 compounds Chemical class 0.000 description 36
• 238000002474 experimental method Methods 0.000 description 34
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 29
• 239000013543 active substance Substances 0.000 description 27
• 206010028851 Necrosis Diseases 0.000 description 25
• 238000000338 in vitro Methods 0.000 description 25
• 229940127089 cytotoxic agent Drugs 0.000 description 24
• 239000002609 medium Substances 0.000 description 22
• 239000011248 coating agent Substances 0.000 description 20
• 238000000576 coating method Methods 0.000 description 20
• 239000000463 material Substances 0.000 description 20
• 101000966429 Chlamydomonas reinhardtii Dynein, 70 kDa intermediate chain, flagellar outer arm Proteins 0.000 description 19
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
• 241000196324 Embryophyta Species 0.000 description 18
• 241000699666 Mus <mouse, genus> Species 0.000 description 18
• 108010002350 Interleukin-2 Proteins 0.000 description 17
• 239000007924 injection Substances 0.000 description 17
• 238000002347 injection Methods 0.000 description 17
• 108700012920 TNF Proteins 0.000 description 16
• 229940090044 injection Drugs 0.000 description 16
• 108090000623 proteins and genes Proteins 0.000 description 16
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 15
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 15
• 239000011162 core material Substances 0.000 description 15
• 241000894007 species Species 0.000 description 15
• 210000004369 blood Anatomy 0.000 description 14
• 239000008280 blood Substances 0.000 description 14
• 230000003993 interaction Effects 0.000 description 14
• 239000002245 particle Substances 0.000 description 14
• 230000002062 proliferating effect Effects 0.000 description 14
• 238000012360 testing method Methods 0.000 description 14
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 13
• 230000001640 apoptogenic effect Effects 0.000 description 13
• 230000022131 cell cycle Effects 0.000 description 13
• 229960004316 cisplatin Drugs 0.000 description 13
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 13
• 230000001939 inductive effect Effects 0.000 description 13
• 229960001756 oxaliplatin Drugs 0.000 description 13
• 229940068196 placebo Drugs 0.000 description 13
• 239000000902 placebo Substances 0.000 description 13
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 12
• 230000027455 binding Effects 0.000 description 12
• 229960000684 cytarabine Drugs 0.000 description 12
• 229960003668 docetaxel Drugs 0.000 description 12
• 229960005277 gemcitabine Drugs 0.000 description 12
• 238000009650 gentamicin protection assay Methods 0.000 description 12
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 12
• 229920000642 polymer Polymers 0.000 description 12
• 102000004169 proteins and genes Human genes 0.000 description 12
• 230000002829 reductive effect Effects 0.000 description 12
• -1 romedae Species 0.000 description 12
• 239000003826 tablet Substances 0.000 description 12
• 230000000259 anti-tumor effect Effects 0.000 description 11
• 238000003556 assay Methods 0.000 description 11
• 229960004679 doxorubicin Drugs 0.000 description 11
• 230000004044 response Effects 0.000 description 11
• 102000004127 Cytokines Human genes 0.000 description 10
• 108090000695 Cytokines Proteins 0.000 description 10
• 241000276498 Pollachius virens Species 0.000 description 10
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 10
• 230000001472 cytotoxic effect Effects 0.000 description 10
• 230000002950 deficient Effects 0.000 description 10
• 235000018102 proteins Nutrition 0.000 description 10
• 230000009467 reduction Effects 0.000 description 10
• 238000007920 subcutaneous administration Methods 0.000 description 10
• 206010015150 Erythema Diseases 0.000 description 9
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
• 206010027476 Metastases Diseases 0.000 description 9
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin-C1 Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 9
• 231100000433 cytotoxic Toxicity 0.000 description 9
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
• 210000002889 endothelial cell Anatomy 0.000 description 9
• 231100000321 erythema Toxicity 0.000 description 9
• 150000002148 esters Chemical class 0.000 description 9
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 9
• 210000004408 hybridoma Anatomy 0.000 description 9
• 230000028993 immune response Effects 0.000 description 9
• 230000001965 increasing effect Effects 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 230000009401 metastasis Effects 0.000 description 9
• 239000012071 phase Substances 0.000 description 9
• 239000002953 phosphate buffered saline Substances 0.000 description 9
• 238000010186 staining Methods 0.000 description 9
• 230000004083 survival effect Effects 0.000 description 9
• 230000002195 synergetic effect Effects 0.000 description 9
• 229960003454 tamoxifen citrate Drugs 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 210000004881 tumor cell Anatomy 0.000 description 9
• 229960002066 vinorelbine Drugs 0.000 description 9
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 9
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 8
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
• 244000067602 Chamaesyce hirta Species 0.000 description 8
• 108020004414 DNA Proteins 0.000 description 8
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 8
• 102100025390 Integrin beta-2 Human genes 0.000 description 8
• 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 8
• 241001529936 Murinae Species 0.000 description 8
• 239000012980 RPMI-1640 medium Substances 0.000 description 8
• 108700022368 Whn Proteins 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 239000004480 active ingredient Substances 0.000 description 8
• 239000000654 additive Substances 0.000 description 8
• 230000000996 additive effect Effects 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 230000008485 antagonism Effects 0.000 description 8
• 239000000969 carrier Substances 0.000 description 8
• 230000000295 complement effect Effects 0.000 description 8
• 230000009089 cytolysis Effects 0.000 description 8
• 239000012636 effector Substances 0.000 description 8
• 230000012010 growth Effects 0.000 description 8
• 230000006698 induction Effects 0.000 description 8
• 229940002612 prodrug Drugs 0.000 description 8
• 239000000651 prodrug Substances 0.000 description 8
• 230000035899 viability Effects 0.000 description 8
• 241000271566 Aves Species 0.000 description 7
• WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 7
• 238000011740 C57BL/6 mouse Methods 0.000 description 7
• 102000003952 Caspase 3 Human genes 0.000 description 7
• 108090000397 Caspase 3 Proteins 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 241000221017 Euphorbiaceae Species 0.000 description 7
• 108060003951 Immunoglobulin Proteins 0.000 description 7
• 238000011579 SCID mouse model Methods 0.000 description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
• 230000000890 antigenic effect Effects 0.000 description 7
• 229940041181 antineoplastic drug Drugs 0.000 description 7
• 210000000481 breast Anatomy 0.000 description 7
• 229950004398 broxuridine Drugs 0.000 description 7
• 230000002209 hydrophobic effect Effects 0.000 description 7
• 210000002865 immune cell Anatomy 0.000 description 7
• 102000018358 immunoglobulin Human genes 0.000 description 7
• 230000006054 immunological memory Effects 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 210000002510 keratinocyte Anatomy 0.000 description 7
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 7
• 229960000485 methotrexate Drugs 0.000 description 7
• 108090000765 processed proteins & peptides Proteins 0.000 description 7
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 229960001603 tamoxifen Drugs 0.000 description 7
• 230000000699 topical effect Effects 0.000 description 7
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
• 108010069236 Goserelin Proteins 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 108090000174 Interleukin-10 Proteins 0.000 description 6
• 108090001005 Interleukin-6 Proteins 0.000 description 6
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 229940100198 alkylating agent Drugs 0.000 description 6
• 239000002168 alkylating agent Substances 0.000 description 6
• 230000002424 anti-apoptotic effect Effects 0.000 description 6
• 230000010261 cell growth Effects 0.000 description 6
• 229960004397 cyclophosphamide Drugs 0.000 description 6
• 238000010790 dilution Methods 0.000 description 6
• 239000012895 dilution Substances 0.000 description 6
• 229960005420 etoposide Drugs 0.000 description 6
• 229960002949 fluorouracil Drugs 0.000 description 6
• 239000000499 gel Substances 0.000 description 6
• 230000005847 immunogenicity Effects 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 210000002540 macrophage Anatomy 0.000 description 6
• 108020004999 messenger RNA Proteins 0.000 description 6
• 239000002207 metabolite Substances 0.000 description 6
• 229910052757 nitrogen Inorganic materials 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 210000001082 somatic cell Anatomy 0.000 description 6
• 229960004528 vincristine Drugs 0.000 description 6
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 5
• 108010092160 Dactinomycin Proteins 0.000 description 5
• 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 5
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
• 231100000002 MTT assay Toxicity 0.000 description 5
• 238000000134 MTT assay Methods 0.000 description 5
• 229930012538 Paclitaxel Natural products 0.000 description 5
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
• 239000002269 analeptic agent Substances 0.000 description 5
• 210000000628 antibody-producing cell Anatomy 0.000 description 5
• 239000011230 binding agent Substances 0.000 description 5
• 229960004562 carboplatin Drugs 0.000 description 5
• 210000001072 colon Anatomy 0.000 description 5
• 229960003901 dacarbazine Drugs 0.000 description 5
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 5
• 230000007812 deficiency Effects 0.000 description 5
• 229960002918 doxorubicin hydrochloride Drugs 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 239000012894 fetal calf serum Substances 0.000 description 5
• 230000004927 fusion Effects 0.000 description 5
• 230000009036 growth inhibition Effects 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 229940088597 hormone Drugs 0.000 description 5
• 239000005556 hormone Substances 0.000 description 5
• 230000002163 immunogen Effects 0.000 description 5
• 239000007943 implant Substances 0.000 description 5
• 230000000977 initiatory effect Effects 0.000 description 5
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 5
• 229960004338 leuprorelin Drugs 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 229960002985 medroxyprogesterone acetate Drugs 0.000 description 5
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
• 229960001924 melphalan Drugs 0.000 description 5
• 210000000822 natural killer cell Anatomy 0.000 description 5
• 229960001592 paclitaxel Drugs 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 238000007619 statistical method Methods 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 230000001988 toxicity Effects 0.000 description 5
• 231100000419 toxicity Toxicity 0.000 description 5
• 229960002110 vincristine sulfate Drugs 0.000 description 5
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 4
• 108010006654 Bleomycin Proteins 0.000 description 4
• 229920002785 Croscarmellose sodium Polymers 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 4
• 108090001007 Interleukin-8 Proteins 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 4
• 238000002679 ablation Methods 0.000 description 4
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 229940009456 adriamycin Drugs 0.000 description 4
• 150000001408 amides Chemical class 0.000 description 4
• 230000003042 antagnostic effect Effects 0.000 description 4
• 239000003242 anti bacterial agent Substances 0.000 description 4
• 230000000340 anti-metabolite Effects 0.000 description 4
• 229940100197 antimetabolite Drugs 0.000 description 4
• 239000002256 antimetabolite Substances 0.000 description 4
• 210000003719 b-lymphocyte Anatomy 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 230000005907 cancer growth Effects 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• 239000013043 chemical agent Substances 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
• 229960004630 chlorambucil Drugs 0.000 description 4
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
• 229960000978 cyproterone acetate Drugs 0.000 description 4
• 229960000640 dactinomycin Drugs 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 201000010099 disease Diseases 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 210000003989 endothelium vascular Anatomy 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 210000002950 fibroblast Anatomy 0.000 description 4
• 239000000945 filler Substances 0.000 description 4
• 238000000684 flow cytometry Methods 0.000 description 4
• 229960002074 flutamide Drugs 0.000 description 4
• 239000008187 granular material Substances 0.000 description 4
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
• 229960001101 ifosfamide Drugs 0.000 description 4
• 230000016784 immunoglobulin production Effects 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 235000019359 magnesium stearate Nutrition 0.000 description 4
• 229960004961 mechlorethamine Drugs 0.000 description 4
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 4
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 4
• 229960004857 mitomycin Drugs 0.000 description 4
• NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 4
• 239000013641 positive control Substances 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 230000000644 propagated effect Effects 0.000 description 4
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 4
• 210000002784 stomach Anatomy 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
• AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 4
• 229920002554 vinyl polymer Polymers 0.000 description 4
• OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
• 206010015866 Extravasation Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• 108010000817 Leuprolide Proteins 0.000 description 3
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 241001494479 Pecora Species 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 102000003923 Protein Kinase C Human genes 0.000 description 3
• 108090000315 Protein Kinase C Proteins 0.000 description 3
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
• 238000000692 Student's t-test Methods 0.000 description 3
• 230000005867 T cell response Effects 0.000 description 3
• 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 239000008186 active pharmaceutical agent Substances 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 230000001464 adherent effect Effects 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 150000001413 amino acids Chemical group 0.000 description 3
• 229960001220 amsacrine Drugs 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
• 229960002092 busulfan Drugs 0.000 description 3
• 238000004364 calculation method Methods 0.000 description 3
• 230000004611 cancer cell death Effects 0.000 description 3
• 229960005243 carmustine Drugs 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 230000000973 chemotherapeutic effect Effects 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• 238000013270 controlled release Methods 0.000 description 3
• 229960000975 daunorubicin Drugs 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 239000007884 disintegrant Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 238000012377 drug delivery Methods 0.000 description 3
• 229940088679 drug related substance Drugs 0.000 description 3
• 229960003265 epirubicin hydrochloride Drugs 0.000 description 3
• 210000003743 erythrocyte Anatomy 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 238000013265 extended release Methods 0.000 description 3
• 230000036251 extravasation Effects 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
• 229940049654 glyceryl behenate Drugs 0.000 description 3
• 230000003054 hormonal effect Effects 0.000 description 3
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 230000002147 killing effect Effects 0.000 description 3
• 238000009533 lab test Methods 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 244000144972 livestock Species 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 229920002521 macromolecule Polymers 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
• 230000011278 mitosis Effects 0.000 description 3
• 230000000394 mitotic effect Effects 0.000 description 3
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
• 229960001156 mitoxantrone Drugs 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 230000001613 neoplastic effect Effects 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 230000037311 normal skin Effects 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 230000001766 physiological effect Effects 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 239000003642 reactive oxygen metabolite Substances 0.000 description 3
• 230000007115 recruitment Effects 0.000 description 3
• 238000000611 regression analysis Methods 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 210000000813 small intestine Anatomy 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 210000004989 spleen cell Anatomy 0.000 description 3
• 230000003068 static effect Effects 0.000 description 3
• 239000011550 stock solution Substances 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 125000004149 thio group Chemical group *S* 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• 238000012762 unpaired Student’s t-test Methods 0.000 description 3
• JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• 206010067484 Adverse reaction Diseases 0.000 description 2
• 241000272517 Anseriformes Species 0.000 description 2
• 241000512290 Antalis Species 0.000 description 2
• 102000015790 Asparaginase Human genes 0.000 description 2
• 108010024976 Asparaginase Proteins 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 241000700198 Cavia Species 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 241001448862 Croton Species 0.000 description 2
• 101150074775 Csf1 gene Proteins 0.000 description 2
• 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
• 102000000541 Defensins Human genes 0.000 description 2
• 108010002069 Defensins Proteins 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 241000283074 Equus asinus Species 0.000 description 2
• 241000704053 Euphorbia lurida Species 0.000 description 2
• 241001553687 Euphorbia misella Species 0.000 description 2
• 241001553737 Euphorbia spathulata Species 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
• 229930182566 Gentamicin Natural products 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 241000558295 Homalanthus Species 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
• 108010021717 Nafarelin Proteins 0.000 description 2
• 108010016076 Octreotide Proteins 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 241000286209 Phasianidae Species 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 108700012411 TNFSF10 Proteins 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
• 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
• 230000035508 accumulation Effects 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000010398 acute inflammatory response Effects 0.000 description 2
• 230000006838 adverse reaction Effects 0.000 description 2
• 229930013930 alkaloid Natural products 0.000 description 2
• 229940098174 alkeran Drugs 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 229960000473 altretamine Drugs 0.000 description 2
• 229960003437 aminoglutethimide Drugs 0.000 description 2
• 229960002932 anastrozole Drugs 0.000 description 2
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 230000001028 anti-proliverative effect Effects 0.000 description 2
• 238000011319 anticancer therapy Methods 0.000 description 2
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 229960000997 bicalutamide Drugs 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
• 229960004117 capecitabine Drugs 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000032823 cell division Effects 0.000 description 2
• 230000003833 cell viability Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 229920002301 cellulose acetate Polymers 0.000 description 2
• 208000006990 cholangiocarcinoma Diseases 0.000 description 2
• 229940105442 cisplatin injection Drugs 0.000 description 2
• 229960002436 cladribine Drugs 0.000 description 2
• 239000008119 colloidal silica Substances 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000010835 comparative analysis Methods 0.000 description 2
• 229960001681 croscarmellose sodium Drugs 0.000 description 2
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
• 238000002784 cytotoxicity assay Methods 0.000 description 2
• 231100000263 cytotoxicity test Toxicity 0.000 description 2
• 229960003109 daunorubicin hydrochloride Drugs 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
• 238000009505 enteric coating Methods 0.000 description 2
• 239000002702 enteric coating Substances 0.000 description 2
• 229940075383 etoposide injection Drugs 0.000 description 2
• 229960000752 etoposide phosphate Drugs 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
• 229960000961 floxuridine Drugs 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 229940081995 fluorouracil injection Drugs 0.000 description 2
• 229960004783 fotemustine Drugs 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
• 229960002913 goserelin Drugs 0.000 description 2
• 210000003714 granulocyte Anatomy 0.000 description 2
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 239000000017 hydrogel Substances 0.000 description 2
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 229960000908 idarubicin Drugs 0.000 description 2
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 229960001375 lactose Drugs 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 229960003881 letrozole Drugs 0.000 description 2
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000011344 liquid material Substances 0.000 description 2
• 229960002247 lomustine Drugs 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 208000019420 lymphoid neoplasm Diseases 0.000 description 2
• 230000002101 lytic effect Effects 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
• 229960004296 megestrol acetate Drugs 0.000 description 2
• 229960001428 mercaptopurine Drugs 0.000 description 2
• 229940080182 methotrexate injection Drugs 0.000 description 2
• 231100000782 microtubule inhibitor Toxicity 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 2
• 229930014626 natural product Natural products 0.000 description 2
• 230000001338 necrotic effect Effects 0.000 description 2
• 229960002653 nilutamide Drugs 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 230000035699 permeability Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 239000004014 plasticizer Substances 0.000 description 2
• 239000004417 polycarbonate Substances 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229940069328 povidone Drugs 0.000 description 2
• 229960004618 prednisone Drugs 0.000 description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 229960004432 raltitrexed Drugs 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 2
• 229960004964 temozolomide Drugs 0.000 description 2
• 229960001278 teniposide Drugs 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• 229960004982 vinblastine sulfate Drugs 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• 229940033942 zoladex Drugs 0.000 description 2
• DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
• MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
• MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
• PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 1
• XIFVTSIIYVGRHJ-UHFFFAOYSA-N 2-n,2-n,4-n,4-n,6-n-pentamethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N(C)C)=NC(N(C)C)=N1 XIFVTSIIYVGRHJ-UHFFFAOYSA-N 0.000 description 1
• UQOWJJGOQJONCI-UHFFFAOYSA-N 20-deoxyingenol-3-angelate Natural products CC1CC2C(C)(C)C2C2C=C(C)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O UQOWJJGOQJONCI-UHFFFAOYSA-N 0.000 description 1
• AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• ZGMLACURZVGTPK-UHFFFAOYSA-N 5-fluoranyl-1h-pyrimidine-2,4-dione Chemical compound OC1=NC=C(F)C(O)=N1.FC1=CNC(=O)NC1=O ZGMLACURZVGTPK-UHFFFAOYSA-N 0.000 description 1
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
• 241001249944 Abbreviata Species 0.000 description 1
• 241001060350 Acalypha Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 241000933112 Acidoton Species 0.000 description 1
• 241001300714 Actinostemon Species 0.000 description 1
• 241001303063 Adelia <angiosperm> Species 0.000 description 1
• 241001303039 Adenocline Species 0.000 description 1
• 241001300216 Adenophaedra Species 0.000 description 1
• 241001554343 Agrostistachys Species 0.000 description 1
• 241001554332 Alchornea Species 0.000 description 1
• 241001303001 Alchorneopsis Species 0.000 description 1
• 241000545417 Aleurites Species 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
• 241000867852 Amanoa Species 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
• 241001542137 Anacampseros Species 0.000 description 1
• 241000867911 Andrachne Species 0.000 description 1
• 235000015072 Antidesma Nutrition 0.000 description 1
• 241000785806 Antidesma Species 0.000 description 1
• 241001249101 Aporosa Species 0.000 description 1
• 241000310770 Argythamnia Species 0.000 description 1
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 241001300645 Astrococcus Species 0.000 description 1
• 241001300062 Baliospermum Species 0.000 description 1
• 235000021357 Behenic acid Nutrition 0.000 description 1
• 241000558349 Bernardia Species 0.000 description 1
• 240000005220 Bischofia javanica Species 0.000 description 1
• 235000010893 Bischofia javanica Nutrition 0.000 description 1
• 241001300032 Blachia Species 0.000 description 1
• 208000004860 Blast Crisis Diseases 0.000 description 1
• 241001300698 Bonania Species 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• 241000219193 Brassicaceae Species 0.000 description 1
• 241000405421 Breynia Species 0.000 description 1
• 241000785605 Bridelia Species 0.000 description 1
• 235000004936 Bromus mango Nutrition 0.000 description 1
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000071092 Candelabrum Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241001300197 Caperonia Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 235000014653 Carica parviflora Nutrition 0.000 description 1
• 241001303011 Caryodendron Species 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000869021 Celianella Species 0.000 description 1
• 241001300690 Cephalocroton Species 0.000 description 1
• 241000366955 Chaenotheca Species 0.000 description 1
• 241000785810 Chaetocarpus Species 0.000 description 1
• 241000944318 Cheilosa Species 0.000 description 1
• 108010014414 Chemokine CXCL2 Proteins 0.000 description 1
• 102000016951 Chemokine CXCL2 Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 241001300185 Chiropetalum Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 241000785597 Cleistanthus Species 0.000 description 1
• 241001300651 Cnesmone Species 0.000 description 1
• 241000243321 Cnidaria Species 0.000 description 1
• 241001300671 Cnidoscolus Species 0.000 description 1
• 241000944184 Coccoceras Species 0.000 description 1
• 241000990192 Codiaeum Species 0.000 description 1
• 241000870753 Conceveiba Species 0.000 description 1
• 241000870724 Croizatia Species 0.000 description 1
• 241001300103 Crotonopsis Species 0.000 description 1
• DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
• DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
• 239000012623 DNA damaging agent Substances 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 241001554488 Dalechampia Species 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• 108020005199 Dehydrogenases Proteins 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 241000868948 Didymocistus Species 0.000 description 1
• 241000266013 Dimorphocalyx Species 0.000 description 1
• 241000867854 Discocarpus Species 0.000 description 1
• 241000819742 Ditaxis <mantid lacewing> Species 0.000 description 1
• MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
• 241001060713 Drypetes Species 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 241000558350 Dysopsis Species 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 241001554477 Elateriospermum Species 0.000 description 1
• 241000558344 Endospermum Species 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 241000016998 Erismanthus Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 241001553302 Euphorbia aaron-rossii Species 0.000 description 1
• 241000704034 Euphorbia acerensis Species 0.000 description 1
• 241000116144 Euphorbia acuta Species 0.000 description 1
• 241001553293 Euphorbia alta Species 0.000 description 1
• 241001553159 Euphorbia angusta Species 0.000 description 1
• 241001373717 Euphorbia anthonyi Species 0.000 description 1
• 241001373703 Euphorbia arabica Species 0.000 description 1
• 241001373446 Euphorbia arizonica Species 0.000 description 1
• 241001191295 Euphorbia arteagae Species 0.000 description 1
• 241001082383 Euphorbia baselicis Species 0.000 description 1
• 241000704022 Euphorbia bergeri Species 0.000 description 1
• 241001553254 Euphorbia bicolor Species 0.000 description 1
• 241001553252 Euphorbia bifurcata Species 0.000 description 1
• 241001553250 Euphorbia bilobata Species 0.000 description 1
• 241001191291 Euphorbia brachiata Species 0.000 description 1
• 241000093820 Euphorbia brachycera Species 0.000 description 1
• 241001618844 Euphorbia caesia Species 0.000 description 1
• 241001553233 Euphorbia calcicola Species 0.000 description 1
• 241001373282 Euphorbia capitellata Species 0.000 description 1
• 241001373278 Euphorbia carmenensis Species 0.000 description 1
• 241001553150 Euphorbia carunculata Species 0.000 description 1
• 241001599902 Euphorbia celastroides Species 0.000 description 1
• 241001373713 Euphorbia chamaerrhodos Species 0.000 description 1
• 241000210641 Euphorbia chamaesula Species 0.000 description 1
• 241001373256 Euphorbia cinerascens Species 0.000 description 1
• 241001191285 Euphorbia colorata Species 0.000 description 1
• 241000093825 Euphorbia commutata Species 0.000 description 1
• 241000210643 Euphorbia creberrima Species 0.000 description 1
• 241000210644 Euphorbia crenulata Species 0.000 description 1
• 241001599887 Euphorbia cubensis Species 0.000 description 1
• 244000048459 Euphorbia cyathophora Species 0.000 description 1
• 241001553148 Euphorbia degeneri Species 0.000 description 1
• 241001373268 Euphorbia deltoidea Species 0.000 description 1
• 241001599890 Euphorbia dentata Species 0.000 description 1
• 241001373244 Euphorbia dioeca Species 0.000 description 1
• 241000498739 Euphorbia dussii Species 0.000 description 1
• 241001553564 Euphorbia eanophylla Species 0.000 description 1
• 241001553561 Euphorbia eglandulosa Species 0.000 description 1
• 241001553555 Euphorbia eriantha Species 0.000 description 1
• 241000221085 Euphorbia esula Species 0.000 description 1
• 241001553525 Euphorbia exstipulata Species 0.000 description 1
• 241001373250 Euphorbia fendleri Species 0.000 description 1
• 241001373251 Euphorbia florida Species 0.000 description 1
• 241001373253 Euphorbia geyeri Species 0.000 description 1
• 241001373239 Euphorbia glyptosperma Species 0.000 description 1
• 241001373234 Euphorbia gracillima Species 0.000 description 1
• 241001553506 Euphorbia gradyi Species 0.000 description 1
• 241001553807 Euphorbia graminea Species 0.000 description 1
• 241001191151 Euphorbia guadalajarana Species 0.000 description 1
• 241001300734 Euphorbia guentheri Species 0.000 description 1
• 241001553803 Euphorbia hedyotoides Species 0.000 description 1
• 241000789809 Euphorbia helenae Species 0.000 description 1
• 241000210605 Euphorbia helleri Species 0.000 description 1
• 241001191145 Euphorbia hexagona Species 0.000 description 1
• 241001191128 Euphorbia hinkleyorum Species 0.000 description 1
• 241001373241 Euphorbia hooveri Species 0.000 description 1
• 241000072948 Euphorbia humistrata Species 0.000 description 1
• 244000106376 Euphorbia hypericifolia Species 0.000 description 1
• 241001553794 Euphorbia jaliscensis Species 0.000 description 1
• 241001373698 Euphorbia jejuna Species 0.000 description 1
• 241001553793 Euphorbia juttae Species 0.000 description 1
• 241000356166 Euphorbia knuthii Species 0.000 description 1
• 241001373338 Euphorbia lasiocarpa Species 0.000 description 1
• 241001373340 Euphorbia lata Species 0.000 description 1
• 241000498513 Euphorbia ledienii Species 0.000 description 1
• 241001373352 Euphorbia leucophylla Species 0.000 description 1
• 241001373354 Euphorbia linguiformis Species 0.000 description 1
• 241000355770 Euphorbia lugardae Species 0.000 description 1
• 241000817985 Euphorbia lupulina Species 0.000 description 1
• 241001191122 Euphorbia lycioides Species 0.000 description 1
• 241001191117 Euphorbia macropodoides Species 0.000 description 1
• 241001379537 Euphorbia melanadenia Species 0.000 description 1
• 241001373324 Euphorbia mendezii Species 0.000 description 1
• 241001373326 Euphorbia mertonii Species 0.000 description 1
• 241001191114 Euphorbia mexiae Species 0.000 description 1
• 241001373328 Euphorbia micromera Species 0.000 description 1
• 241001373330 Euphorbia missurica Species 0.000 description 1
• 241001373318 Euphorbia multiformis Species 0.000 description 1
• 241001600122 Euphorbia nutans Species 0.000 description 1
• 241001553675 Euphorbia oaxacana Species 0.000 description 1
• 241001373312 Euphorbia olowaluana Species 0.000 description 1
• 241001379530 Euphorbia parishii Species 0.000 description 1
• 241001373692 Euphorbia parryi Species 0.000 description 1
• 241001373304 Euphorbia pediculifera Species 0.000 description 1
• 241000210612 Euphorbia peplidion Species 0.000 description 1
• 241001373298 Euphorbia perlignea Species 0.000 description 1
• 241001373693 Euphorbia petrina Species 0.000 description 1
• 241001191102 Euphorbia pinetorum Species 0.000 description 1
• 241001373300 Euphorbia pionosperma Species 0.000 description 1
• 241001600106 Euphorbia poeppigii Species 0.000 description 1
• 241001373071 Euphorbia polycarpa Species 0.000 description 1
• 241001553145 Euphorbia polycnemoides Species 0.000 description 1
• 241001191099 Euphorbia polyphylla Species 0.000 description 1
• 241000704074 Euphorbia portulacoides Species 0.000 description 1
• 241000652460 Euphorbia procumbens Species 0.000 description 1
• 244000062608 Euphorbia prostrata Species 0.000 description 1
• 241001553778 Euphorbia pteroneura Species 0.000 description 1
• 241000704065 Euphorbia purpurea Species 0.000 description 1
• 241000097488 Euphorbia rapulum Species 0.000 description 1
• 241001373694 Euphorbia remyi Species 0.000 description 1
• 241001373069 Euphorbia revoluta Species 0.000 description 1
• 241001553755 Euphorbia robusta Species 0.000 description 1
• 241001177582 Euphorbia saxatilis Species 0.000 description 1
• 241000210614 Euphorbia schizoloba Species 0.000 description 1
• 241000704097 Euphorbia sclerocyathium Species 0.000 description 1
• 241001599919 Euphorbia sect. Cubanthus Species 0.000 description 1
• 241001553742 Euphorbia segoviensis Species 0.000 description 1
• 241001618891 Euphorbia seguieriana Species 0.000 description 1
• 241000244736 Euphorbia serpillifolia Species 0.000 description 1
• 241001373182 Euphorbia serrula Species 0.000 description 1
• 241001373183 Euphorbia setiloba Species 0.000 description 1
• 241001553558 Euphorbia sinclairiana Species 0.000 description 1
• 241001553739 Euphorbia sonorae Species 0.000 description 1
• 241001191091 Euphorbia soobyi Species 0.000 description 1
• 241001600080 Euphorbia stellata Species 0.000 description 1
• 241001553723 Euphorbia subpeltata Species 0.000 description 1
• 241001553722 Euphorbia succedanea Species 0.000 description 1
• 241000500281 Euphorbia telephioides Species 0.000 description 1
• 241000210615 Euphorbia tetrapora Species 0.000 description 1
• 244000256297 Euphorbia tirucalli Species 0.000 description 1
• 241000210624 Euphorbia tuerckheimii Species 0.000 description 1
• 241001570576 Euphorbia turczaninowii Species 0.000 description 1
• 241000704100 Euphorbia umbellata Species 0.000 description 1
• 241001373162 Euphorbia umbellulata Species 0.000 description 1
• 241001373158 Euphorbia villifera Species 0.000 description 1
• 241001570573 Euphorbia whitei Species 0.000 description 1
• 241001191073 Euphorbia xanti Species 0.000 description 1
• 241000500277 Euphorbia xylopoda Species 0.000 description 1
• 241000789111 Excoecaria Species 0.000 description 1
• 208000001382 Experimental Melanoma Diseases 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 241000785753 Flueggea Species 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 241001300136 Gavarretia Species 0.000 description 1
• 241000221018 Gelonium Species 0.000 description 1
• 238000002738 Giemsa staining Methods 0.000 description 1
• 241001301420 Givotia Species 0.000 description 1
• 241000421432 Glochidion Species 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 101710162684 Glyceraldehyde-3-phosphate dehydrogenase 3 Proteins 0.000 description 1
• 241001303044 Glycydendron Species 0.000 description 1
• 241000282575 Gorilla Species 0.000 description 1
• 241000608174 Gymnadenia Species 0.000 description 1
• 241001300749 Gymnanthes Species 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 244000043261 Hevea brasiliensis Species 0.000 description 1
• 241000869029 Hieronyma Species 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 241000868951 Hymenocardia Species 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 241000221089 Jatropha Species 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 241000870766 Lasiocroton Species 0.000 description 1
• 241001303065 Leucocroton Species 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• 241001300746 Mabea Species 0.000 description 1
• 241001561070 Macaranga Species 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 229930184510 Mallotus Natural products 0.000 description 1
• 241001060384 Mallotus <angiosperm> Species 0.000 description 1
• 240000007228 Mangifera indica Species 0.000 description 1
• 235000014826 Mangifera indica Nutrition 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 241000789133 Maprounea Species 0.000 description 1
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
• 241000221024 Mercurialis Species 0.000 description 1
• 229920003091 Methocel™ Polymers 0.000 description 1
• 241000558300 Micrandra Species 0.000 description 1
• 241000404165 Microcephala Species 0.000 description 1
• 244000085338 Microdesmis Species 0.000 description 1
• 241001300738 Microstachys Species 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 241000711408 Murine respirovirus Species 0.000 description 1
• 241000204031 Mycoplasma Species 0.000 description 1
• LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 241000558292 Neoscortechinia Species 0.000 description 1
• 241001639851 Nephradenia Species 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 241000870767 Omphalea Species 0.000 description 1
• 241001300642 Ophellantha Species 0.000 description 1
• 241001280335 Orbiculariae Species 0.000 description 1
• 241000558287 Ostodes Species 0.000 description 1
• 241000602295 Oxydectes Species 0.000 description 1
• 241000366197 Paludicola Species 0.000 description 1
• 241001300042 Pausandra Species 0.000 description 1
• 241001387976 Pera Species 0.000 description 1
• 241001387969 Petalostigma Species 0.000 description 1
• 241001130943 Phyllanthus <Aves> Species 0.000 description 1
• 241000789129 Pimelodendron Species 0.000 description 1
• 241000951867 Piranhea Species 0.000 description 1
• 241001300673 Platygyna Species 0.000 description 1
• 208000002151 Pleural effusion Diseases 0.000 description 1
• 241001300677 Plukenetia Species 0.000 description 1
• 241000870720 Podocalyx Species 0.000 description 1
• 101100505672 Podospora anserina grisea gene Proteins 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 235000014258 Polygonum bistorta Nutrition 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
• 241001301608 Pycnocoma Species 0.000 description 1
• 241000867913 Reverchonia Species 0.000 description 1
• 241000867892 Richeria Species 0.000 description 1
• 241001333412 Richeriella Species 0.000 description 1
• 241000789127 Ricinocarpos Species 0.000 description 1
• 241000556257 Rupicola <angiosperm> Species 0.000 description 1
• 230000018199 S phase Effects 0.000 description 1
• 241001300086 Sagotia Species 0.000 description 1
• 241000994241 Sapium Species 0.000 description 1
• 244000057114 Sapium sebiferum Species 0.000 description 1
• 241000785917 Savia Species 0.000 description 1
• 244000078613 Scirpus geniculatus Species 0.000 description 1
• 241001301432 Sclerocroton Species 0.000 description 1
• 241000867909 Securinega Species 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 241001273190 Spathiostemon Species 0.000 description 1
• 241001354228 Spixia Species 0.000 description 1
• 235000009184 Spondias indica Nutrition 0.000 description 1
• 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 241000789520 Strophioblachia Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
• 230000033540 T cell apoptotic process Effects 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 241001537924 Tetracoccus <angiosperm> Species 0.000 description 1
• 241001300663 Tetraplandra Species 0.000 description 1
• 241000870728 Tetrorchidium Species 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• 241001300199 Thyrsanthera Species 0.000 description 1
• 241000566916 Tomentella Species 0.000 description 1
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
• IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
• 241000870682 Trigonostemon Species 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
• 241000789056 Tyria Species 0.000 description 1
• 241000863480 Vinca Species 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 208000009621 actinic keratosis Diseases 0.000 description 1
• 230000006786 activation induced cell death Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 229940060238 agrylin Drugs 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 108700025316 aldesleukin Proteins 0.000 description 1
• 229960005310 aldesleukin Drugs 0.000 description 1
• 125000005210 alkyl ammonium group Chemical group 0.000 description 1
• 229920013820 alkyl cellulose Polymers 0.000 description 1
• 150000005215 alkyl ethers Chemical class 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 229960003942 amphotericin b Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
• 229960003555 anagrelide hydrochloride Drugs 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000000843 anti-fungal effect Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 238000011394 anticancer treatment Methods 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 229940078010 arimidex Drugs 0.000 description 1
• 229940087620 aromasin Drugs 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
• 229950011321 azaserine Drugs 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 229940116226 behenic acid Drugs 0.000 description 1
• 150000001556 benzimidazoles Chemical class 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000003851 biochemical process Effects 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• 229960004395 bleomycin sulfate Drugs 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229940088954 camptosar Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 238000003163 cell fusion method Methods 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 230000000349 chemoimmunotherapeutic effect Effects 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 229920003211 cis-1,4-polyisoprene Polymers 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 102000006834 complement receptors Human genes 0.000 description 1
• 108010047295 complement receptors Proteins 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229940088547 cosmegen Drugs 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000003235 crystal violet staining Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 229940034075 cytarabine injection Drugs 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 229940104368 daunorubicin injection Drugs 0.000 description 1
• 229940107841 daunoxome Drugs 0.000 description 1
• 238000010908 decantation Methods 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 239000000412 dendrimer Substances 0.000 description 1
• 229920000736 dendritic polymer Polymers 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• 229940063223 depo-provera Drugs 0.000 description 1
• 231100000223 dermal penetration Toxicity 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
• 150000005690 diesters Chemical class 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 238000002845 discoloration Methods 0.000 description 1
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 229940120655 eloxatin Drugs 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
• 229950002017 esorubicin Drugs 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 229960000255 exemestane Drugs 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 229940043168 fareston Drugs 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 229940087476 femara Drugs 0.000 description 1
• 239000012997 ficoll-paque Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 229960005304 fludarabine phosphate Drugs 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 210000003953 foreskin Anatomy 0.000 description 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
• 229960002258 fulvestrant Drugs 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
• 229940020967 gemzar Drugs 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930182480 glucuronide Natural products 0.000 description 1
• 150000008134 glucuronides Chemical class 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 239000003163 gonadal steroid hormone Substances 0.000 description 1
• XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
• 229960003690 goserelin acetate Drugs 0.000 description 1
• 230000009422 growth inhibiting effect Effects 0.000 description 1
• 210000004209 hair Anatomy 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 229940003183 hexalen Drugs 0.000 description 1
• 238000010562 histological examination Methods 0.000 description 1
• 230000008348 humoral response Effects 0.000 description 1
• 229940088013 hycamtin Drugs 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 230000036571 hydration Effects 0.000 description 1
• 238000006703 hydration reaction Methods 0.000 description 1
• 229940096120 hydrea Drugs 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• 229960002899 hydroxyprogesterone Drugs 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000002434 immunopotentiative effect Effects 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 230000005917 in vivo anti-tumor Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000007154 intracellular accumulation Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229960001021 lactose monohydrate Drugs 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229940063725 leukeran Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
• 229940087857 lupron Drugs 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 229950000547 mafosfamide Drugs 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 235000005739 manihot Nutrition 0.000 description 1
• 241001515942 marmosets Species 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229940090004 megace Drugs 0.000 description 1
• 230000015654 memory Effects 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000004200 microcrystalline wax Substances 0.000 description 1
• 235000019808 microcrystalline wax Nutrition 0.000 description 1
• 239000012982 microporous membrane Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• 229940090009 myleran Drugs 0.000 description 1
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• 229960004309 nafarelin acetate Drugs 0.000 description 1
• 239000002077 nanosphere Substances 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000017095 negative regulation of cell growth Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229960005419 nitrogen Drugs 0.000 description 1
• 229940085033 nolvadex Drugs 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 229960002700 octreotide Drugs 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 238000010397 one-hybrid screening Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 229940127084 other anti-cancer agent Drugs 0.000 description 1
• 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
• 238000007500 overflow downdraw method Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 238000002135 phase contrast microscopy Methods 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229920002689 polyvinyl acetate Polymers 0.000 description 1
• 239000011118 polyvinyl acetate Substances 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229940124606 potential therapeutic agent Drugs 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 235000013594 poultry meat Nutrition 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 229940063222 provera Drugs 0.000 description 1
• 229940117820 purinethol Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 238000005067 remediation Methods 0.000 description 1
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 201000006845 reticulosarcoma Diseases 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 229940072272 sandostatin Drugs 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 210000001732 sebaceous gland Anatomy 0.000 description 1
• 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 210000001626 skin fibroblast Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229960004518 sodium iodide (131i) Drugs 0.000 description 1
• 229940080313 sodium starch Drugs 0.000 description 1
• FVAUCKIRQBBSSJ-LAIFMVDKSA-M sodium;iodine-131(1-) Chemical compound [Na+].[131I-] FVAUCKIRQBBSSJ-LAIFMVDKSA-M 0.000 description 1
• 239000002689 soil Substances 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 238000007614 solvation Methods 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 229940086546 synarel Drugs 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 238000009492 tablet coating Methods 0.000 description 1
• 239000002700 tablet coating Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 239000006068 taste-masking agent Substances 0.000 description 1
• 238000003419 tautomerization reaction Methods 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 229960002190 topotecan hydrochloride Drugs 0.000 description 1
• 229960004167 toremifene citrate Drugs 0.000 description 1
• 238000011426 transformation method Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 229940032510 trelstar Drugs 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• 150000005691 triesters Chemical group 0.000 description 1
• 229930187845 trigonostemon Natural products 0.000 description 1
• IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
• 229960001082 trimethoprim Drugs 0.000 description 1
• 229960001099 trimetrexate Drugs 0.000 description 1
• NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
• 229960004824 triptorelin Drugs 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000002476 tumorcidal effect Effects 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 229940061389 viadur Drugs 0.000 description 1
• KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• COFJBSXICYYSKG-FJFFLIEUSA-N vindesine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 COFJBSXICYYSKG-FJFFLIEUSA-N 0.000 description 1
• 229960005212 vindesine sulfate Drugs 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 229960002166 vinorelbine tartrate Drugs 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000007762 w/o emulsion Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229940053867 xeloda Drugs 0.000 description 1